ENTA – Enanta Pharmaceuticals Inc
Float Short %
10.23
Margin Of Safety %
Put/Call OI Ratio
0.37
EPS Next Q Diff
0.33
EPS Last/This Y
1.54
EPS This/Next Y
-0.2
Price
14.6
Target Price
19.12
Analyst Recom
1.38
Performance Q
63.86
Relative Volume
0.46
Beta
0.97
Ticker: ENTA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | ENTA | 11.5 | 0.89 | 0.00 | 2631 |
| 2025-11-11 | ENTA | 12.02 | 0.89 | 0.00 | 2631 |
| 2025-11-12 | ENTA | 11.92 | 0.87 | 0.10 | 2666 |
| 2025-11-13 | ENTA | 11.71 | 0.86 | 0.00 | 2675 |
| 2025-11-14 | ENTA | 12.05 | 0.89 | 0.06 | 2624 |
| 2025-11-17 | ENTA | 12.82 | 0.89 | 0.00 | 2631 |
| 2025-11-18 | ENTA | 12.36 | 0.52 | 0.03 | 3695 |
| 2025-11-19 | ENTA | 12.15 | 0.52 | 11.77 | 3716 |
| 2025-11-20 | ENTA | 12.11 | 0.58 | 1.01 | 3882 |
| 2025-11-21 | ENTA | 12.71 | 0.61 | 1.56 | 4024 |
| 2025-11-24 | ENTA | 13.66 | 0.19 | 0.96 | 2442 |
| 2025-11-25 | ENTA | 13.64 | 0.18 | 0.03 | 2459 |
| 2025-11-26 | ENTA | 13.91 | 0.25 | 0.93 | 2686 |
| 2025-12-01 | ENTA | 14.14 | 0.26 | 2.00 | 2713 |
| 2025-12-02 | ENTA | 13.95 | 0.26 | 43.00 | 2726 |
| 2025-12-03 | ENTA | 14.25 | 0.37 | 0.00 | 2963 |
| 2025-12-04 | ENTA | 14.11 | 0.37 | 0.00 | 2963 |
| 2025-12-05 | ENTA | 14.58 | 0.37 | 0.56 | 2981 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | ENTA | 11.51 | 25.4 | - | -3.72 |
| 2025-11-11 | ENTA | 12.04 | 25.4 | - | -3.72 |
| 2025-11-12 | ENTA | 11.93 | 25.4 | - | -3.72 |
| 2025-11-13 | ENTA | 11.69 | 25.4 | - | -3.72 |
| 2025-11-14 | ENTA | 12.03 | 25.4 | - | -3.72 |
| 2025-11-17 | ENTA | 12.84 | 25.4 | - | -3.72 |
| 2025-11-18 | ENTA | 12.37 | 25.4 | - | -3.72 |
| 2025-11-19 | ENTA | 12.13 | 25.4 | - | -3.72 |
| 2025-11-20 | ENTA | 12.12 | 25.4 | - | -3.15 |
| 2025-11-21 | ENTA | 12.72 | 49.5 | - | -2.98 |
| 2025-11-24 | ENTA | 13.71 | 49.5 | - | -2.98 |
| 2025-11-25 | ENTA | 13.66 | 49.5 | - | -2.30 |
| 2025-11-26 | ENTA | 13.94 | 49.5 | - | -2.30 |
| 2025-12-01 | ENTA | 14.15 | 49.1 | - | -2.30 |
| 2025-12-02 | ENTA | 13.96 | 49.1 | - | -2.30 |
| 2025-12-03 | ENTA | 14.24 | 49.1 | - | -2.30 |
| 2025-12-04 | ENTA | 14.08 | 49.1 | - | -2.30 |
| 2025-12-05 | ENTA | 14.60 | 49.1 | - | -2.30 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | ENTA | 0.00 | -1.49 | 10.44 |
| 2025-11-11 | ENTA | 0.00 | -1.49 | 10.44 |
| 2025-11-12 | ENTA | 0.00 | -1.49 | 10.14 |
| 2025-11-13 | ENTA | 0.00 | -1.49 | 10.14 |
| 2025-11-14 | ENTA | 0.00 | -1.49 | 9.98 |
| 2025-11-17 | ENTA | 0.00 | 27.11 | 9.98 |
| 2025-11-18 | ENTA | 0.00 | 27.11 | 9.98 |
| 2025-11-19 | ENTA | 0.00 | 27.11 | 9.98 |
| 2025-11-20 | ENTA | 0.00 | 27.11 | 9.98 |
| 2025-11-21 | ENTA | 0.00 | 27.11 | 9.98 |
| 2025-11-24 | ENTA | 0.00 | 15.65 | 9.98 |
| 2025-11-25 | ENTA | 0.00 | 15.65 | 9.98 |
| 2025-11-26 | ENTA | 0.00 | 15.65 | 10.23 |
| 2025-12-01 | ENTA | 0.00 | 15.62 | 10.23 |
| 2025-12-02 | ENTA | 0.00 | 15.62 | 10.23 |
| 2025-12-03 | ENTA | 0.00 | 15.62 | 10.23 |
| 2025-12-04 | ENTA | -0.04 | 15.62 | 10.23 |
| 2025-12-05 | ENTA | -0.04 | 15.62 | 10.23 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.87
Avg. EPS Est. Current Quarter
-0.54
Avg. EPS Est. Next Quarter
-0.54
Insider Transactions
-0.04
Institutional Transactions
15.62
Beta
0.97
Average Sales Estimate Current Quarter
16
Average Sales Estimate Next Quarter
15
Fair Value
Quality Score
19
Growth Score
24
Sentiment Score
77
Actual DrawDown %
85.7
Max Drawdown 5-Year %
-95.6
Target Price
19.12
P/E
Forward P/E
PEG
P/S
6.45
P/B
4.82
P/Free Cash Flow
EPS
-3.84
Average EPS Est. Cur. Y
-2.3
EPS Next Y. (Est.)
-2.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-125.36
Relative Volume
0.46
Return on Equity vs Sector %
-153.4
Return on Equity vs Industry %
-138.5
EPS 1 7Days Diff
1
EPS 1 30Days Diff
0.97
EBIT Estimation
Enanta Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 120
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today
news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance
stock history ENTA – Enanta Pharmaceuticals Inc invest stock market
stock prices ENTA premarket after hours
ticker ENTA fair value insiders trading